Jyong Biotech Ltd. MENS
1.78 USD -0.09 (-4.81%)
At closeNov 3, 2026, 4:00 PM EST
1.78 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
1.71 Day range 1.91
1.43 52-week range 43.78
- YTD
- -54.94%
- 1 year
- -95.83%
- Market cap
- 135.33M
- EPS (ttm)
- -0.06
- Shares out
- 76.03M
- YTD return
- -54.94%
- 1-year return
- -95.83%
- Volume
- 90.69K
- Avg volume
- 41.31K
- Open
- 1.90
- Previous close
- 1.87
- Day's range
- 1.71 – 1.91
- 52-week range
- 1.43 – 43.78
2Y -8.33 (-82.39%)
Key statistics
- Enterprise value
- 1.16B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -1.73M
- Total cash
- 98.00K
- Total debt
- 18.14M
- Return on equity
- 0.00%
- Short % of float
- 0.45%
- 50-day average
- 40.49
- 200-day average
- 36.26
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
MENS Revenue — quarterly 47.68M
MENS Net income — quarterly 2.69M
MENS EPS — quarterly 0.26
About Jyong Biotech Ltd.
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Taiwan
- Website
- jyongbio.com
News
Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California 
Jyong Biotech Plans Potential Texas Manufacturing Facility And U.S. Operations Center To Support Future Commercialization Of Drug Candidates 
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates 
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow 
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships 
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention 
12 Health Care Stocks Moving In Monday's After-Market Session 
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview 
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 
Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages
Your note
Sign in to keep a note on MENS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.07% | 53,844 | 157.22K | Sep 29, 2025 |
| HRT Financial LP | 0.03% | 20,819 | 60.79K | Sep 29, 2025 |
| Millennium Management Llc | 0.02% | 13,013 | 38.00K | Sep 29, 2025 |
| Citadel Advisors Llc | 0.02% | 12,641 | 36.91K | Sep 29, 2025 |
| BNP Paribas Financial Markets | 0.00% | 1,698 | 4.96K | Sep 29, 2025 |
| UBS Group AG | 0.00% | 537 | 1.57K | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.05% | 35,802 | 104.54K | Sep 29, 2025 |
| Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF | 0.02% | 18,042 | 52.68K | Sep 29, 2025 |